Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entresto versus valsartan on cognition in HFpEF
2016-001254-17Phase 3Unknown
- Sponsor
- Novartis
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and heart failure (HF) comparing Entresto arm with Valsartan arm (2 arms). Primary endpoint: Change from baseline to 3 years in CogState Global Cognitive Composite Score. Status: unknown.
02
Drugs
sacubitril + valsartanvalsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure (HF)
Beyond the preview
Go deeper on 2016-001254-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001254-17.